Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Paediatric research

Montelukast shows promise for treating children with 5/5 ALOX5 genetic variant, study suggests

Subgroup analysis indicated that montelukast outperformed placebo in children with the 5/5 ALOX5 variant.

Chemical structure of Montelukast drug

Source: Molekuul.be / Alamy

Genetics plays a part in the efficacy of montelukast (pictured) in children

Montelukast is a leukotriene receptor antagonist used to treat wheeze but its value in young children is unproven. The WAIT trial therefore assessed the effectiveness of intermittently dosed montelukast in 1,358 children aged 10 months to 5 years.

Study results reported in The Lancet Respiratory Medicine (online, 9 September 2014)[1] show that montelukast was no more effective than placebo for reducing unscheduled medical attendances for wheezing episodes. However, subgroup analysis indicated that the treatment benefit varied according to the arachidonate 5-lipoxygenase (ALOX5) promoter genotype, with montelukast outperforming placebo in children with the 5/5 ALOX5 variant.

“Further data from stratified trials are needed before treatment is targeted to a responsive subgroup,” conclude Jonathan Grigg, from Queen Mary University of London, and co-authors.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066434

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Essentials of Economic Evaluation in Healthcare

    Essentials of Economic Evaluation in Healthcare

    An introduction to economic evaluation specific to healthcare, for those with little or no knowledge of economics. Covers cost effectiveness, cost utility and cost benefit analysis.

    £33.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.